Abstract: In some embodiments, a method selects a collection for an interface, wherein a collection includes one or more instances of content. A theme is selected from a plurality of themes for the collection. A first theme in the plurality of themes includes one or more tiles that is displayed in a larger area compared to a second theme that includes one or more tiles that is displayed in a smaller area. The method sends information for the theme and the collection to a client device to indicate to the interface the theme to use to display the collection.

Abstract: In some embodiments, a method selects a collection for an interface, wherein a collection includes one or more instances of content. A theme is selected from a plurality of themes for the collection. A first theme in the plurality of themes includes one or more tiles that is displayed in a larger area compared to a second theme that includes one or more tiles that is displayed in a smaller area. The method sends information for the theme and the collection to a client device to indicate to the interface the theme to use to display the collection.

Abstract: In some embodiments, a method receives a context for a user account and selects a plurality of collections for an interface. A collection includes one or more instances of content. The method analyzes a context for a user account to select a theme from a plurality of themes for a collection in the plurality of collections. The themes in the plurality of themes apply different display formats to the collection. The method sends an identifier for the theme and information for the collection to a client device being used by the user account to indicate to the interface the theme to use to display the collection with the plurality of collections.

Abstract: The present invention provides bispecific antigen-binding molecules characterized by comprising a first and a second domain, each binding to any of CS1, BCMA, CD20, CD22, FLT3, CD123, CLL1, MSLN, CDH3 or EpCAM, a third domain binding to an extracellular epitope of the human and the Macaca CD3? chain and optionally a fourth domain, which is a Fc modality. Moreover, the invention provides a polynucleotide, encoding the antigen-binding molecule, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

Abstract: In some embodiments, a method receives a context for a user account and selects a plurality of collections for an interface. A collection includes one or more instances of content. The method analyzes a context for a user account to select a theme from a plurality of themes for a collection in the plurality of collections. The themes in the plurality of themes apply different display formats to the collection. The method sends an identifier for the theme and information for the collection to a client device being used by the user account to indicate to the interface the theme to use to display the collection with the plurality of collections.

Abstract: In some embodiments, a method selects a context for a user account and selects a plurality of collections for an interface. A collection includes a set of videos. The method selects a theme from a plurality of themes for a collection in the plurality of collections based on the context. The plurality of themes apply different display formats to the collection. The method sends an identifier for the theme and information for the collection to a client device being used by the user account to indicate to the interface the theme to use to display the collection with the plurality of collections.

Abstract: In some embodiments, a method selects a context for a user account and selects a plurality of collections for an interface. A collection includes a set of videos. The method selects a theme from a plurality of themes for a collection in the plurality of collections based on the context. The plurality of themes apply different display formats to the collection. The method sends an identifier for the theme and information for the collection to a client device being used by the user account to indicate to the interface the theme to use to display the collection with the plurality of collections.

Abstract: The present invention provides machines, compositions and methods for producing bionanocatalysts (BNCs) comprising one or more enzymes selected from a broad spectrum of industrially and medically important enzymes. The BNCs are self-assembled and magnetically immobilized enzymes. The machines, compositions, and methods are fully scalable from bench top to industrial manufacturing volumes.

Abstract: The present invention provides machines, compositions and methods for producing bionanocatalysts (BNCs) comprising one or more enzymes selected from a broad spectrum of industrially and medically important enzymes. The BNCs are self-assembled and magnetically immobilized enzymes. The machines, compositions, and methods are fully scalable from bench top to industrial manufacturing volumes.

Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Abstract: The present invention provides machines, compositions and methods for producing bionanocatalysts (BNCs) comprising one or more enzymes selected from a broad spectrum of industrially and medically important enzymes. The BNCs are self-assembled and magnetically immobilized enzymes. The machines, compositions, and methods are fully scalable from bench top to industrial manufacturing volumes.

Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.